Drug Profile
MK 7680
Alternative Names: MK-7680Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Hepatitis-C in Belgium (PO, Capsule)
- 01 Apr 2015 Merck Sharp & Dohme completes a phase I trial in Hepatitis C in Belgium (NCT02269059)
- 01 Dec 2014 Phase-I clinical trials in Hepatitis C in Belgium (PO) (NCT02269059)